DelSiTech Revenue
Pharmaceutical Manufacturing • 
Turku, Southwest Finland, Finland • 51-100 Employees
DelSiTech revenue & valuation
| Annual revenue | $8,700,000 |
| Revenue per employee | $145,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $27,900,000 |
| Total funding | $10,900,000 |
Key Contacts at DelSiTech
Marcus John Reay
Director Of Business Development
Sari Kievari
Director, Head Of Clinical Operations
Marceline Akieh-Pirkanniemi
Director, Head Of Analytical Development
Hanna Arstila
Director, Head Of Formulation Development
Mina Irenius
Quality Director
Heikki Niskanen
Quality Director
Sakari Karhuvaara
Medical Director
Company overview
| Headquarters | Itäinen Pitkäkatu 4 c, Turku, Southwest Finland 20520, FI |
| Phone number | +35822510110 |
| Website | |
| NAICS | 3254 |
| SIC | 283 |
| Keywords | Biodegradable Silica-Based Drug Release, Controlled, Intravitreal Drug Delivery, Supergeneric Drug Development |
| Founded | 2001 |
| Employees | 51-100 |
| Socials |
DelSiTech Email Formats
DelSiTech uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@delsitech.com), used 71.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@delsitech.com | 71.7% |
{first name}.{last name} | john.doe@delsitech.com | 22.6% |
{2char} | {2char}@delsitech.com | 5.7% |
About DelSiTech
DelSiTech is a drug delivery and drug development company based in Turku, Finland. DelSiTech has developed a unique proprietary technology making it a world leader in advanced biodegradable silica-based drug delivery. The technology has successfully been applied to the controlled release of small molecules, biopharmaceuticals and viral vectors with a focus on parenteral and local administration. We can work with you from early feasibility testing to clinical proof of concept; the technology can also be licensed to industry partners. With the DelSiTechTMSilica Matrix, we can create novel products, provide alternative administration opportunities, and extend and manage the life cycle of existing products. More patient-friendly products can be developed which release active compounds over days to many months. The technology is also well suited for challenging drug delivery needs such as controlled local delivery to the eye or the brain. At DelSiTech, we are also developing our own in-house supergeneric drug products for significant unmet medical and market needs.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
DelSiTech has 16 employees across 9 departments.
Departments
Number of employees
DelSiTech Tech Stack
Discover the technologies and tools that power DelSiTech's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Cookie compliance
JavaScript libraries
Maps
JavaScript libraries
Web servers
JavaScript libraries
Programming languages
Security
Blogs
Analytics
New Zealand
United Kingdom
Germany
United States
Australia
Frequently asked questions
4.8
40,000 users
